Posted on: 10/02/2026

Announcing More Life Science Companies Taking Part in Investor Conference 

Next week we bring you the inaugural Life Sciences Investor Day at Emergence, in partnership with Wholesale Investor featuring more than 30 companies across biotech, medtech and devices, healthcare and pharmaceuticals.

Emergence 2026 is a premier investment conference for high-net-worth and professional investors.

This is a dedicated platform for investors to gain direct access to promising companies in the life sciences sector, from FDA-fast-tracked cancer therapies to AI-driven diagnostics – opportunities shaping the next decade of innovation.

Some of the featured companies taking part in Emergence 2026 include:

  • ARIA Research — Growing Augmented Reality (AR) audio technology empowering blind users through co-designed solutions.
  • Snoretox – World‑first muscle‑toning treatment improving function in weak or injured muscles across species.
  • Luminoma Diagnostics Ltd – Commercialising AI device diagnosing skin cancer instantly, reducing missed cancers and unnecessary biopsies.
  • Biotome — Peptide diagnostics platform enabling ultra-sensitive, patentable tests, preventing disease through detection.
  • Carelogix — Digital care platform improving safety, speed, and connectivity while reducing provider paperwork.
  • Atherid Therapeutics Pty Ltd – First‑in‑class therapy targeting plaque directly to reduce the progression of cardiovascular disease.
  • WRS Bioproducts Pty Ltd – Developing scalable natural ingredient production with proprietary harvesting, extraction, and CO₂‑sequestration technology.
  • Respiradigm – Optimising non‑steroidal asthma therapies targeting upstream inflammation, improving global outcomes through safer, earlier interventions.
  • INOVIQ Limited (ASX: IIQ) – Advancing exosome diagnostics and therapeutics to transform global cancer care.
  • Amplia Therapeutics – Enhancing potent oral FAK inhibitors for cancer and fibrotic diseases, progressing clinical trials with FDA recognition.
  • Medasyst – Innovating medication delivery with proprietary technology, improving compliance, outcomes, and reducing healthcare costs.
  • Arovella Therapeutics (ASX: ALA) – Advancing oncology  therapies with innovative off‑the‑shelf CAR‑iNKT cell technology for patients worldwide.
  • Alterity Therapeutics – Late-clinical stage biotech company advancing ATH434 for Multiple System Atrophy and other neurodegenerative diseases, with positive results in a Phase 2 trial and now progressing towards a Phase 3 trial.
  • Inova Medical – Early-stage medtech startup delivering innovative, sustainable healthcare solutions for real clinical needs.
  • Incisive Technologies – FDA‑approved dental device detects early tooth decay, enabling prevention‑first care and reducing treatment costs globally.
  • Canopy Blue – Transforming native seaweed into sustainable, nature‑positive solutions that restore oceans and empower communities.
  • Wavewise Analytics* – Non‑invasive continuous monitoring empowers clinicians with early neurological deterioration detection.
  • Navi Medical Technologies* – Transforming vascular access with ECG‑guided placement and continuous surveillance, improving safety for patients of all ages.
  • VenstraMedical* – Backed by Highcroft Capital, with Mayo Clinic validation, 120+ years MedTech expertise, and patented next‑gen cardiac pVAD.
  • ELLIS Medical Solutions* – Healthcare innovator delivering efficient, award‑winning solutions to elevate patient outcomes and industry standards.
  • Patrys Limited* – Clinical‑stage biotech, developing first injectable delirium therapy, proprietary deoxymab platform, de‑risked pathway, $2B+ market.
  • Encapsolutions* – Patented SkinSync® nanofiber platform, 72‑hour delivery, U.S. traction, global IP, expert team, scalable wellness therapeutics.
  • Astraea Technologies* – Extreme‑environment healthcare innovator, backed by research partnerships, pioneering validation platforms, addressing frontier safety markets globally.
  • Cortical Dynamics* – Clinical‑stage neurotech, Philips‑backed, patented AI monitor, dual anaesthesia‑pain metrics, de‑risked trials, $2.5B market.
  • Servatus Biopharmaceuticals* – Advancing patented dual drug platforms, targeting first-line and adjunct treatments for autoimmune, inflammatory, infectious conditions
  • Eudaemon Technologies* – Innovative sexual and reproductive health and wellness (SRH & W) platform, backed by FDA‑cleared materials, Industry 4.0 expertise, targeting $150B Lifetech market

MTPConnect is backing this initiative through the  MTPConnect Investor Ready Program which aims to enhance life science companies’ readiness for investment and connecting companies directly with Wholesale Investor’s network of over 45,000 investors. Through the program which opened in November 2025, MTPConnect has been assisting participating companies with their capital raising requirements through a curated package of activities provided by Wholesale Investor.

During the day, two panel sessions will feature leading success stories and investment minds to help investors build their own  investment thesis for approaching this unique opportunity.

  • Spotlight on Life Sciences: Success Stories & The Next High-Growth Wave – with MTPConnect’s Lisa Dubé, Dimerix’s Dr Robert Shepherd, Proto Axiom’s Anthony Liveris, Artesian’s Stephanie Morris and 4D Medical’s Andreas Fouras.
  • Investing in Intelligence: The Convergence of AI & Digital Health – with MTPConnect’s Dr Erin McAllum, ANDHealth’s Bronwyn Le Grice, Adelaide University’s Dr Michelle Perugini, Harrison.ai’s Dr Mark Phillips

Event Details:

  • Date: 18 – 20 February 2026
  • Venue: Four Seasons Hotel, Sydney
  • Audience: 750+ HNWIs, family offices, and institutional investors focused on life sciences

* companies featured on Day 2 or 3 of Emergence 2024 

MTPConnect acknowledges the traditional custodians of Australia. We pay our respects to elders past, present and future, of all Aboriginal and Torres Strait Islander nations.

WALSIH MTPConnect SA